Quality and readability of drug fact sheets for FDA-approved and emergency use authorised drug products for COVID-19 treatment: an observational study.

ABSTRACT:

Objectives

To determine the quality of drug manufacturers' fact sheets for patients for COVID-19 therapeutics for baricitinib, convalescent plasma, anakinra, molnupiravir, nirmatrelvir/ritonavir, remdesivir, tocilizumab and vilobelimab, and fact sheet readability.

Design

Cross-sectional document analysis.

Setting

Fact sheets on COVID-19 drugs approved by the US Food and Drug Administration from 2020 to 2023.

Primary and secondary outcome measures

Quality assessments with the 16-item DISCERN tool scored 16-80 points and 36-item Ensuring Quality of Information for Patients (EQIP) tool scored 0-36, where lower scores indicate low-quality information. We assessed readability with Flesch-Kincaid Reading Ease (ranges from 0 to 100 where higher scores correspond to re

SUBMITTER: Pranic SM 

PROVIDER: S-EPMC12530376 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature